These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26484961)

  • 1. The Role of Positron Emission Tomography/Computed Tomography in Management and Prediction of Survival in Pancreatic Cancer.
    Nunna P; Sheikhbahaei S; Ahn S; Young B; Subramaniam RM
    J Comput Assist Tomogr; 2016; 40(1):142-51. PubMed ID: 26484961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
    Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
    Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
    Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.
    Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P
    J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer.
    Zhang J; Zuo CJ; Jia NY; Wang JH; Hu SP; Yu ZF; Zheng Y; Zhang AY; Feng XY
    World J Gastroenterol; 2015 Mar; 21(10):2988-96. PubMed ID: 25780297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staging accuracy of pancreatic cancer: comparison between non-contrast-enhanced and contrast-enhanced PET/CT.
    Yoneyama T; Tateishi U; Endo I; Inoue T
    Eur J Radiol; 2014 Oct; 83(10):1734-9. PubMed ID: 25043494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT).
    Cameron K; Golan S; Simpson W; Peti S; Roayaie S; Labow D; Kostakoglu L
    Abdom Imaging; 2011 Aug; 36(4):463-71. PubMed ID: 21465110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ¹⁸F-FDG PET/CT imaging of the pancreas: spectrum of diseases.
    Nguyen VX; Nguyen CC; Nguyen BD
    JOP; 2011 Nov; 12(6):557-66. PubMed ID: 22072244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging.
    Grueneisen J; Nagarajah J; Buchbender C; Hoffmann O; Schaarschmidt BM; Poeppel T; Forsting M; Quick HH; Umutlu L; Kinner S
    Invest Radiol; 2015 Aug; 50(8):505-13. PubMed ID: 26115367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability of target and normal structure delineation using multimodality imaging for radiation therapy of pancreatic cancer.
    Dalah E; Moraru I; Paulson E; Erickson B; Li XA
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):633-40. PubMed ID: 24755533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer.
    Wang XY; Yang F; Jin C; Fu DL
    World J Gastroenterol; 2014 Nov; 20(42):15580-9. PubMed ID: 25400441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/CT of cancer patients: part 1, pancreatic neoplasms.
    Dibble EH; Karantanis D; Mercier G; Peller PJ; Kachnic LA; Subramaniam RM
    AJR Am J Roentgenol; 2012 Nov; 199(5):952-67. PubMed ID: 23096166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and peri-ampullary cancers.
    Burge ME; O'Rourke N; Cavallucci D; Bryant R; Francesconi A; Houston K; Wyld D; Eastgate M; Finch R; Hopkins G; Thomas P; Macfarlane D
    HPB (Oxford); 2015 Jul; 17(7):624-31. PubMed ID: 25929273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solid pseudopapillary pancreatic tumor mimicking a neuroendocrine neoplasm on ¹⁸F-FDOPA PET/CT.
    Imperiale A; Addeo P; Averous G; Namer IJ; Bachellier P
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2643-4. PubMed ID: 23671317
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.